Progesterone With an Estradiol Patch: Understanding Dose and Schedule

Published Jul 14, 2025Updated Oct 12, 2026Last reviewed Aug 29, 2026

10 linked public sourcesEditorial, sourcing, and corrections policy

An estradiol patch strength does not, by itself, identify the right progesterone regimen. The question involves both dose and schedule: which progesterone product, by which route, on which days, and in what menopause context? Understanding those details helps distinguish 100 mg every day and 200 mg on scheduled days.

First, confirm what the patch number means

A patch marked 0.05 mg/day has a nominal delivery rate of 50 micrograms per day. It is not a weekly total. Likewise, 0.075 mg/day equals 75 micrograms/day, while 0.75 mg/day equals 750 micrograms/day. These are unit calculations, not conversions of clinical potency between formulations.

The decimal matters. A 0.75 mg/day strength is not among the printed strengths of the named U.S. patches discussed here. Do not assume that an entry reading “0.75” means “0.075.” Copy the exact package or prescription wording and have a pharmacist clarify an unclear entry. A number such as 0.75 may also describe a gel amount, which is different from a patch’s daily-delivery notation. [1–4]

Keep the daily rate separate from the replacement schedule. A patch can deliver estradiol each day while being replaced weekly or twice weekly. Product starting doses and the fuller strength comparison belong in the adult estradiol patch dosing guide.

Why progesterone is paired with systemic estrogen

For someone with a uterus, systemic estrogen generally requires a progestogen to protect the endometrium—the uterine lining—from estrogen-driven overgrowth. Estradiol patch labels discuss this need but do not provide a progesterone-to-estradiol milligram ratio or one progesterone dose for every patch strength. [1–3]

“Progestogen” is the broader drug category; micronized progesterone is one specific option. The exact product and route matter. An oral capsule regimen cannot simply be transferred to vaginal use or a skin cream. The evidence below concerns specified oral progesterone or guideline regimens. It does not establish interchangeable endometrial protection across routes.

What the U.S. progesterone label actually establishes

The current U.S. Prometrium label describes oral micronized progesterone 200 mg as a single bedtime dose for 12 sequential days per 28-day cycle. Its labeled endometrial-hyperplasia prevention context is postmenopausal women with a uterus receiving daily oral conjugated estrogen tablets. That labeled combination used oral estrogen rather than a patch.

The supporting three-year endometrial trial used that progesterone schedule alongside oral conjugated equine estrogens, 0.625 mg/day. This is evidence for a defined combination and schedule. It does not establish that 200 mg is the correct companion to every estradiol patch. Nor should risk estimates from oral conjugated estrogen plus medroxyprogesterone acetate be presented as estimates for a patch plus micronized progesterone. [6]

How UK guidance frames patch pairing

The BMS’s August 2026 practical prescribing guidance addresses symptomatic menopause around ages 45–55, excluding POI dosing. It classifies 75 micrograms/day as medium-dose estradiol and 100 micrograms/day as high-dose. Suggested micronized progesterone regimens for low/medium estrogen are 100 mg continuously or 200 mg sequentially; for high estrogen, 200 mg continuously or 300 mg sequentially. Continuous means daily progestogen; sequential means defined days while estrogen continues. [7] The current BMS bleeding guideline recommends at least 12 days of micronized progesterone per month in a sequential regimen. [9]

These UK clinical guidance suggestions have a different evidence context from the U.S. label example. The June 2026 BMS update explains that higher estrogen warrants higher recommended progestogen even without bleeding, while acknowledging limited robust dose-specific evidence at high estrogen doses. Bleeding at lower estrogen doses can also prompt regimen reassessment. [8]

A regimen includes both the capsule strength and the planned days of use. Do not switch between them by comparing capsule strength alone.

Keep a usable regimen record

For a medication discussion, record the exact estradiol product, daily rate and change days; progesterone product, strength, route and planned days; whether a uterus is present; and whether treatment concerns menopause or POI. Include actual missed applications or capsules, new bleeding and side effects.

This record separates unclear notation from a schedule mismatch or a symptom needing assessment. New, unexplained or persistent bleeding deserves clinical assessment; dose arithmetic cannot identify its cause. Neither a patch number nor the absence of bleeding proves that a particular progesterone regimen provides adequate protection.

Frequently asked questions

Is a 0.05 mg estradiol patch a weekly dose?

A label stating 0.05 mg/day describes nominal daily delivery of 50 micrograms. The replacement interval is printed separately. [1–3]

How often is Vivelle-Dot changed?

Twice weekly, every 3–4 days, according to its label. [1]

How often is Climara changed?

Once weekly, according to its label. [3]

Is Menostar a low-dose hot-flash patch?

Menostar supplies 14 micrograms/day on a weekly calendar and is labeled for postmenopausal osteoporosis prevention. It is not a vasomotor-symptom treatment. [4]

Can I convert oral estradiol directly to a patch dose?

There is no universal oral-to-patch conversion formula in these labels. Unit arithmetic does not establish equivalent clinical dosing across formulations. [1–3]

Should estradiol patches be titrated every four weeks?

Not automatically. The Climara label bases adjustment on clinical response rather than a mandatory four-week increase. [3]

Do I need a blood estradiol target?

These patch labels do not establish a universal serum estradiol target. A blood result alone also does not establish progesterone adequacy. [1–3]

Does everyone with a uterus need the same progesterone dose?

No. The estrogen dose, progesterone product, route and continuous or sequential schedule matter. The U.S. label and UK guidance describe different evidence contexts, not a single universal pairing. [6–8]

What if my patch falls off?

Follow the specific product label. Vivelle-Dot and Minivelle instruct reapplication or replacement if needed while retaining the original change calendar; apply a missed new patch as soon as possible. [1,2]

Is POI dosing the same as routine menopause dosing?

POI has separate bone-health goals. Its guideline conditionally suggests at least 100 micrograms/day transdermal estradiol, or equivalent, with progestogen planning for an intact uterus. The BMS table discussed here excludes POI. [5,7]

References

Two separate progesterone schedule examples: the U.S. Prometrium oral-estrogen label uses 200 mg on 12 days of a 28-day cycle; BMS low or medium estrogen guidance lists 100 mg in a continuous daily regimen. — The examples come from different populations and evidence contexts. Shading illustrates days of use; actual start dates follow the prescribed plan. Image: HealthRX.com original editorial diagramView full-size diagram